The Institute for Clinical and Economic Review on Tuesday, Nov. 13, released a report on the comparative clinical effectiveness and value of biologic treatments for asthma associated with type 2 inflammation and/or allergic asthma.
According to a press release, the report assesses the following therapies:
- Sanofi/Regeneron’s dupilumab (Dupixent);
- Genentech/Novartis’ omalizumab (Xolair); and
- AstraZeneca’s benralizumab (Fasenra).
“All five biologics modestly reduce asthma exacerbation and improve daily quality of live,” ICER Chief Medical Officer Dr. David Rind said in a statement. “However, the treatments’ net prices appear to be far out of alignment with these incremental clinical benefits, and the entire therapy class would need to see price discounts of at least 50% to reach commonly cited thresholds for cost-effectiveness.”
To read ICER’s report, click here.